Aromatase Inhibition in Advanced Prostate Cancer
Author Information
Author(s): R.J. Shearer, J.H. Davies, M. Dowsett, P.R. Malone, A. Hedley, D. Cunningham, R.C. Coombes
Primary Institution: St Georges Hospital, London
Hypothesis
Can the steroidal aromatase inhibitor 4-hydroxyandrostenedione provide pain relief in patients with advanced hormone-resistant prostate cancer?
Conclusion
The study found that 63% of patients experienced significant pain relief from the treatment.
Supporting Evidence
- 63% of patients gained significant pain relief from the treatment.
- 5 patients experienced a transient increase in bone pain after the first injection.
- Complete subjective response was seen in 21% of patients.
Takeaway
Doctors tested a new medicine to help men with severe prostate cancer pain, and many felt better after using it.
Methodology
Patients received weekly intramuscular injections of 4-OHA and were assessed for pain relief using the ECOG scale.
Limitations
The study had a small sample size and lacked formal objective measurements.
Participant Demographics
Patients were aged 58 to 83 years, all had advanced prostate cancer and had previously undergone orchidectomy.
Want to read the original?
Access the complete publication on the publisher's website